International Urology and Nephrology最新文献

{"title":"A nomograph model for predicting the risk of diabetes nephropathy.","authors":"Moli Liu, Zheng Li, Xu Zhang, Xiaoxing Wei","doi":"10.1007/s11255-024-04351-8","DOIUrl":"10.1007/s11255-024-04351-8","url":null,"abstract":"<p><strong>Objective: </strong>Using machine learning to construct a prediction model for the risk of diabetes kidney disease (DKD) in the American diabetes population and evaluate its effect.</p><p><strong>Methods: </strong>First, a dataset of five cycles from 2009 to 2018 was obtained from the National Health and Nutrition Examination Survey (NHANES) database, weighted and then standardized (with the study population in the United States), and the data were processed and randomly grouped using R software. Next, variable selection for DKD patients was conducted using Lasso regression, two-way stepwise iterative regression, and random forest methods. A nomogram model was constructed for the risk prediction of DKD. Finally, the predictive performance, predictive value, calibration, and clinical effectiveness of the model were evaluated through the receipt of ROC curves, Brier score values, calibration curves (CC), and decision curves (DCA). In addition, we will visualize it.</p><p><strong>Results: </strong>A total of 4371 participants were selected and included in this study. Patients were randomly divided into a training set (n = 3066 people) and a validation set (n = 1305 people) in a 7:3 ratio. Using machine learning algorithms and drawing Venn diagrams, five variables significantly correlated with DKD risk were identified, namely Age, Hba1c, ALB, Scr, and TP. The area under the ROC curve (AUC) of the training set evaluation index for this model is 0.735, the net benefit rate of DCA is 2%-90%, and the Brier score is 0.172. The area under the ROC curve of the validation set (AUC) is 0.717, and the DCA curve shows a good net benefit rate. The Brier score is 0.177, and the calibration curve results of the validation set and training set are almost consistent.</p><p><strong>Conclusion: </strong>The DKD risk nomogram model constructed in this study has good predictive performance, which helps to evaluate the risk of DKD as early as possible in clinical practice and formulate relevant intervention and treatment measures. The visual result can be used by doctors or individuals to estimate the probability of DKD risk, as a reference to help make better treatment decisions.</p>","PeriodicalId":14454,"journal":{"name":"International Urology and Nephrology","volume":" ","pages":"1919-1931"},"PeriodicalIF":1.8,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142949084","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Previous maximal transurethral resection of bladder tumor lead to unfavorable perioperative outcomes following radical cystectomy.","authors":"Wentao Ma, Yuan Shui, Guilin Wang, Xiaohua Zhang, Ze Zhang, Zhilong Dong, Junqiang Tian, Yunxin Zhang, Hui Ding, Li Yang, Zhiping Wang","doi":"10.1007/s11255-025-04368-7","DOIUrl":"10.1007/s11255-025-04368-7","url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate the impact of maximal transurethral resection of bladder tumor (TURBT) on perioperative outcomes following radical cystectomy (RC).</p><p><strong>Methods: </strong>This study included 310 patients who underwent RC for the diagnosis of bladder urothelial carcinoma. Of these, 146 patients had a history of maximal TURBT (TURBT group) and 164 did not (non-TURBT group). Patients in the TURBT group were categorized into four groups according to the time interval between the last TURBT and RC: ≤ 1 month, 1-3 months, 3-6 months, and > 6 months. Additionally, the TURBT group was stratified into a single TURBT group and multiple TURBT group. Perioperative outcomes were compared between the groups.</p><p><strong>Results: </strong>The median duration of pelvic drainage tube retention was longer in the TURBT group (11 vs. 9 days, p = 0.037). The incidence of Clavien-Dindo ≥ 3 complications (15.3% vs. 7.3%, p = 0.031) and ICU admission rate(10.4% vs. 4.5%, p = 0.048) were higher in the TURBT group. Statistically significant differences were observed in the incidence of Clavien-Dindo ≥ 3 complications (p = 0.007), reoperation rates (p = 0.041), incidence of sepsis (p = 0.022), and urinary complications (p = 0.024) across the four groups stratified by the time interval between TURBT and RC, with the 1-3 to months group demonstrating the highest incidence. There was no significant difference in perioperative outcomes between patients who underwent a single TURBT and those who underwent multiple TURBT.</p><p><strong>Conclusion: </strong>Patients with a history of maximal TURBT, especially those who underwent RC within 1-3 months after maximal TURBT, have an increased risk of unfavorable perioperative outcomes following RC.</p>","PeriodicalId":14454,"journal":{"name":"International Urology and Nephrology","volume":" ","pages":"1817-1826"},"PeriodicalIF":1.8,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142948460","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The prognostic value of serum testosterone to BMI ratio in Chinese males with prostate cancer treated by androgen deprivation therapy: a single-center study.","authors":"Zhenfei Liu, Xiangyu Zeng, Cheng Li, Jiangang Pan","doi":"10.1007/s11255-024-04349-2","DOIUrl":"10.1007/s11255-024-04349-2","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the prognostic value of serum testosterone combining with body mass index (BMI) on the prostate cancer (PCa) after androgen deprivation therapy (ADT).</p><p><strong>Methods: </strong>In this study, we included the patients from June, 2017 to June, 2022 who were diagnosed with PCa and received ADT. The data of these patients were reviewed and analyzed. The ratio of serum testosterone to BMI (T/BMI) was calculated and the patients were divided into high T/BMI and low T/BMI group based on the optimal T/BMI cutoff value.</p><p><strong>Results: </strong>A total of 84 patients were screened and divided into high T/BMI group (> 0.244) (n = 35) and low T/BMI group (≤ 0.244) (n = 49). Higher possibility of metastasis occurred in low T/BMI than high T/BMI group (P < 0.001) and the PFS in low T/BMI group was significantly lower (P < 0.001) compared to high T/BMI group. Serum testosterone in the high BMI group was significantly lower than that in the non-high BMI group. Testosterone, BMI, and T/BMI were significantly different in the tumor progression group than that in non-tumor progression group (P < 0.05). The result from univariate Cox regression analysis demonstrated that BMI (HR = 1.247, P = 0.001), testosterone (HR = 0.936, P = 0.009), T/BMI(HR = 1.036, P = 0.017), and the metastasis (HR = 1.593, P = 0.025) were significantly correlated with PFS. The result from multivariate Cox regression analysis demonstrated that T/BMI (HR = 1.037, P = 0.015) was significantly correlated with PFS.</p><p><strong>Conclusion: </strong>T/BMI has a certain predicting value for the prognosis and correlated with PFS of the PCa patients. Higher level of BMI and lower level of testosterone are more associated with poor outcomes than those with low BMI and high testosterone.</p>","PeriodicalId":14454,"journal":{"name":"International Urology and Nephrology","volume":" ","pages":"1755-1762"},"PeriodicalIF":1.8,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142948801","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The assistive role of an internal fluid circulatory device in ureteroscopic lithotripsy: a randomized, controlled and prospective study.","authors":"Nenggui Feng, Wei Zhao, Yunxin Xiao, Jiajian Lin, Zhixian Ao, Chengjie Zhang, Guangyao Chen","doi":"10.1007/s11255-024-04359-0","DOIUrl":"10.1007/s11255-024-04359-0","url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate and compare the efficacy of a newly designed in-house assistive internal fluid circulatory device in ureteroscopic lithotripsy for ureteral stones.</p><p><strong>Methods: </strong>In this study, 97 patients were assigned to the trial group and underwent ureteroscopic lithotripsy with an in-house newly designed assistive internal fluid circulatory device; 96 patients were assigned to the control group and underwent traditional ureteroscopic lithotripsy without the assistive device. The primary outcome was the final stone-free rate (SFR) at 1-month post-surgery. Secondary observations included the quality of the surgical field, difficulty experienced during insertion of the ureteroscope, stone migration rate, operative time, change in serum creatinine, changes in the urinary leukocyte count, and perioperative complications.</p><p><strong>Results: </strong>No significant differences were detected between the two groups in terms of gender, age, body mass index, location, or stone burden (P > 0.05). At the 1-month follow-up, the SFR was significantly higher in the trial group than the control group (P < 0.05). Furthermore, the operative time was significantly shorter in the trial group (P < 0.05) with easier ureteroscope insertion relative to the control group (P < 0.05). The incidence of stone migration in the trial group was significantly lower than that in the control group (P < 0.05) and the quality of the surgical field was significantly improved (P < 0.001). No significant differences were detected in terms of serum creatinine levels, urinary leukocyte counts, or perioperative complications (P > 0.05).</p><p><strong>Conclusions: </strong>The application of an assistive internal fluid circulatory device represents an effective and safe method for ureteroscopic lithotripsy.</p>","PeriodicalId":14454,"journal":{"name":"International Urology and Nephrology","volume":" ","pages":"1763-1770"},"PeriodicalIF":1.8,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142948856","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring the link between sex hormone-binding globulin levels and prostate cancer risk: a comprehensive systematic review and meta-analysis.","authors":"Prakasini Satapathy, Shilpa Gaidhane, Ashok Kumar Bishoyi, Subbulakshmi Ganesan, Karthikeyan Jayabalan, Swati Mishra, Manpreet Kaur, Ganesh Bushi, Muhammed Shabil, Rukshar Syed, Sonam Puri, Sunil Kumar, Sabah Ansar, Sanjit Sah, Diptismita Jena, Zaid Khan, Quazi Syed Zahiruddin, Khang Wen Goh","doi":"10.1007/s11255-025-04370-z","DOIUrl":"10.1007/s11255-025-04370-z","url":null,"abstract":"<p><strong>Background: </strong>Sex hormone-binding globulin (SHBG) plays a critical role in regulating androgen bioavailability and has been hypothesized to influence prostate cancer risk, though existing evidence is inconsistent. This systematic review and meta-analysis aimed to evaluate the association between SHBG levels and prostate cancer risk.</p><p><strong>Methods: </strong>A comprehensive search was conducted across PubMed, Embase, and Web of Science for studies published up to December 1, 2024. Observational studies assessing SHBG levels and prostate cancer risk were included. Effect sizes were pooled using random-effects meta-analysis. Heterogeneity was evaluated using the I² statistic, and quality assessment was performed using the Newcastle-Ottawa Scale. Statistical analysis was performed using R software version 4.4.</p><p><strong>Results: </strong>Sixteen studies, including 720,298 participants and 90,799 prostate cancer cases, were analyzed. The pooled odds ratio (OR) for prostate cancer risk per unit increase in SHBG was 0.907 (95% CI 0.799-1.030), indicating no statistically significant association. Substantial heterogeneity was observed among the included studies (I² = 79%; P < 0.0001). Subgroup analyses showed no significant variation in effect sizes by study design. However, a Mendelian randomization analysis conducted in 140,254 European-descent males, including 79,148 prostate cancer cases, suggested a modest protective effect of higher SHBG levels, with an OR of 0.944 (95% CI 0.897-0.993). Sensitivity analyses confirmed the robustness of the pooled findings.</p><p><strong>Conclusion: </strong>This meta-analysis showed a complex relationship between SHBG levels and prostate cancer risk. While overall findings do not support a statistically significant association, higher SHBG levels may confer a protective role in specific contexts. Further research is needed to elucidate mechanisms, reduce heterogeneity, and validate SHBG as a biomarker for risk stratification.</p>","PeriodicalId":14454,"journal":{"name":"International Urology and Nephrology","volume":" ","pages":"1673-1687"},"PeriodicalIF":1.8,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142947884","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Monotropein attenuates renal cell carcinoma cell progression and M2 macrophage polarization by weakening NF-κB.","authors":"Heping Qiu, Fei Liu, Mei Qiu, Juliang Yang, Xiang Peng","doi":"10.1007/s11255-024-04358-1","DOIUrl":"10.1007/s11255-024-04358-1","url":null,"abstract":"<p><strong>Purpose: </strong>The study aimed to investigate the effect and mechanism of monotropein on renal cell carcinoma (RCC).</p><p><strong>Methods: </strong>After monotropein and NF-κB receptor activator (RANKL) treatment, cell proliferation, invasion, and apoptosis were evaluated using CCK-8, Transwell, and flow cytometry. Primary macrophages co-cultured with monotropein-treated RCC cells were analyzed to evaluate macrophage polarization using qRT-PCR, western blot, and ELISA assays by detecting the expression of M2 markers (CD206, CD168) and cytokines (IL-10, TGF-β). Additionally, the therapeutic efficacy of monotropein was examined using an RCC mouse xenograft model.</p><p><strong>Results: </strong>Monotropein could inhibit the proliferation, invasion, and M2 macrophage polarization and accelerate the apoptosis of RCC cells. Mechanistically, monotropein suppressed NF-κB pathway activation in RCC cells and reduced the expression of NF-κB downstream targets, including Bcl-2, c-Myc, and MMP9. RANKL could eliminate the effect of monotropein on RCC progression. In primary macrophages co-cultured with monotropein-treated RCC cells, monotropein downregulated M2 polarization markers and cytokines, further supporting its role in modulating the tumor microenvironment. In mouse models, monotropein reduced RCC tumor growth, induced apoptosis, and blocked NF-κB pathway.</p><p><strong>Conclusions: </strong>Monotropein prevents RCC malignant progression and reduces M2 macrophage polarization by suppressing the NF-κB pathway, suggesting that monotropein may serve as a potential therapeutic agent for RCC by targeting both tumor cells and the tumor microenvironment.</p>","PeriodicalId":14454,"journal":{"name":"International Urology and Nephrology","volume":" ","pages":"1785-1795"},"PeriodicalIF":1.8,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142947930","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term efficacy and catheter choice in male varicocele embolization using NBCA-MS glue.","authors":"Ezio Lanza, Alessandra Mininni, Luigi Tomasino, Angela Ammirabile, Giuseppe Ferrillo, Silvio Romano, Dario Poretti, Marco Francone, Vittorio Pedicini","doi":"10.1007/s11255-024-04347-4","DOIUrl":"10.1007/s11255-024-04347-4","url":null,"abstract":"<p><strong>Purpose: </strong>This study investigated the long-term efficacy of n-butyl-2-cyanoacrylate-metacryloxysulpholane (NBCA-MS) for varicocele embolization (VE) without using a microcatheter.</p><p><strong>Methods: </strong>A retrospective study was conducted on male patients who underwent VE with NBCA-MS for grade III-IV varicocele between January 2016 and December 2022. Patients were categorized by the catheter type used. Telephone interviews assessed long-term effectiveness, focusing on relapse, re-treatment and spermiogram improvements.</p><p><strong>Results: </strong>Of 185 patients, 102 completed the phone interview (median age 25 years, median follow-up 4.1 years). Sixty-six procedures were performed with only an HH1 catheter (Group A, 65%), and 36 required an additional microcatheter (Group B, 35%), with Group A having a shorter median procedure time (30 vs. 36.5 min, p = 0.004). Long-term follow-up indicated a low recurrence rate (12%) and spermiogram improvement among a subset of patients (81%), with no significant difference in long-term efficacy between groups (relapse p = 0.244, re-treatment p = 1). Costs increased by 47-56% when adding a microcatheter plus a 0.018-inch guidewire.</p><p><strong>Conclusion: </strong>The study confirms the effectiveness and safety of VE with NBCA-MS, demonstrating low recurrence rates and improvements in groin discomfort and fertility outcomes. In most cases of varicocele embolization using NBCA-MS, microcatheters can be avoided, reducing procedural costs and duration without compromising long-term efficacy.</p>","PeriodicalId":14454,"journal":{"name":"International Urology and Nephrology","volume":" ","pages":"1707-1714"},"PeriodicalIF":1.8,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142909727","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Complications and outcomes of post-transplant lymphocele management: a 30-year retrospective analysis.","authors":"Oleksandr Boiko, Ignacio Garcia-Alonso, Jesus Padilla, David Lecumberri, Mykola Boiko","doi":"10.1007/s11255-024-04348-3","DOIUrl":"10.1007/s11255-024-04348-3","url":null,"abstract":"<p><strong>Introduction: </strong>Current guidelines recommend percutaneous drainage as the first-line approach for the management of symptomatic lymphoceles following renal transplantation, with surgical fenestration reserved for refractory or recurrent cases. This study evaluates the effectiveness and safety of these therapeutic strategies in renal transplant recipients.</p><p><strong>Methods: </strong>A retrospective analysis of 109 renal transplant recipients with symptomatic lymphoceles treated between 1993 and 2023 at a single public center was conducted. Recipients were followed from lymphocele diagnosis through treatment to resolution.</p><p><strong>Results: </strong>Percutaneous drainage was performed as the initial treatment in 101 recipients, while 8 underwent primary fenestration. Among patients treated with drainage, 43.5% developed infections, with infection risk increasing with catheter placement duration: odds ratio (OR) 2.57 (p = 0.28) at 2 weeks, 15.0 (p = 0.003) at 4 weeks, and 20.2 (p = 0.002) at 6 weeks. Resolution with drainage alone occurred in 54.8% of cases after a median of 39 days. The remaining patients required fenestration as a second-line treatment. No significant difference was observed in the total duration of hospital stay between the two methods.</p><p><strong>Conclusion: </strong>Prolonged percutaneous drainage for post-transplant lymphoceles is associated with high infection rates and limited efficacy, warranting its use primarily for renal function stabilization or diagnostic purposes. Further studies are necessary to investigate alternative management strategies that may improve outcomes and reduce complications in recipients with symptomatic lymphoceles following renal transplantation.</p>","PeriodicalId":14454,"journal":{"name":"International Urology and Nephrology","volume":" ","pages":"1747-1753"},"PeriodicalIF":1.8,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142921133","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of melatonin on drug- or contrast-induced acute kidney injury: a systematic review and GRADE-assessed meta-analysis of experimental and clinical studies.","authors":"Alireza Ghasemi, Mohammadreza Ghasemi, Maryam Rashidian, Fatemeh Bastan, Amir Baghaei","doi":"10.1007/s11255-024-04333-w","DOIUrl":"10.1007/s11255-024-04333-w","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Objective: &lt;/strong&gt;The objective of this systematic review and meta-analysis was to assess the efficacy of melatonin in drug- or contrast-induced AKI in preclinical and clinical studies.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;PubMed, Embase, Scopus, Web of Science (WOS), the Cochrane Database of Systematic Reviews (CDSR), and clinical trials.GOV from the beginning until August 1, 2024. On the basis of the inclusion and exclusion criteria, the articles were included by two independent researchers. Data regarding study design, patient characteristics, the number of patients with and without AKI, and the means and SDs of the serum creatinine and BUN levels were extracted from relevant studies. STATA version 17.0 was used to compute pooled measures of standardized mean differences, standardized mean differences, risk ratios and risk differences. I2 and chi-square tests were used to assess heterogeneity between studies. Funnel plots, Egger tests and the trim-and-fill method were used to evaluate small study effects (publication bias). The risk of bias of the included clinical and preclinical studies was assessed via the Cochrane ROB tool and SYRCLE tool, respectively. The credibility of the results was evaluated via GRADE. Sensitivity analysis was performed via the one-out removal method.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;We identified 1,696 nonduplicate records, of which the full texts of 159 articles were examined. Twenty-nine animal experimental studies and 5 clinical trials met the inclusion criteria and were included in the review. The results of the meta-analysis confirmed that melatonin was significantly effective at reducing the serum creatinine level (standardized mean difference: - 3.04; 95% CI - 3.904 to - 2.183, with 95% prediction interval: - 7.201 to 1.163) and the BUN level (standardized mean difference: - 3.464; 95% CI - 4.378 to - 2.549, with 95% prediction interval: - 7.839 to 0.911) in drug-induced AKI animal studies. Melatonin did not have a significant effect on the serum creatinine level (standardized mean difference: - 2.67; 95% CI - 9.69 to - 4.35, with 95% prediction interval: - 42.618 to 37.278) or the BUN level (standardized mean difference: - 1.77; 95% CI - 5.533 to - 1.994, with 95% prediction interval: -22.943 to 19.404) in contrast-induced AKI animal studies. Furthermore, in clinical studies, melatonin had no significant effect on reducing the serum creatinine level (standardized mean difference: 0.183; 95% CI - 1.309 to 1.675, with 95% prediction interval: - 7.975 to 8.340), BUN level (standardized mean difference: 0.206; 95% CI - 0.0871 to 1.283, with 95% prediction interval: - 5.115 to 5.528) or risk of AKI incidence (risk ratio: 0.877; 95% CI 0.46 to 1.64, with 95% prediction interval: - 0.238 to 3.174; risk difference: - 0.06 mg/dl; 95% CI - 0.259 to 0.40 mg/dl, with 95% prediction interval: - 0.467 to 0.348). There were no significant publication biases, and after sensitivity analysis, no considerable changes we","PeriodicalId":14454,"journal":{"name":"International Urology and Nephrology","volume":" ","pages":"1865-1883"},"PeriodicalIF":1.8,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142949062","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Low-frequency bladder vibration for the treatment of urinary tract infections in spinal cord injury patients with neurogenic bladder.","authors":"Yingying Zhang, Ping Cai, Xiaoyan Feng, Qian Yang, Haifang Wang","doi":"10.1007/s11255-024-04353-6","DOIUrl":"10.1007/s11255-024-04353-6","url":null,"abstract":"<p><strong>Purpose: </strong>Evaluate if low-frequency bladder vibration (LFBV) combined with clean intermittent catheterization (CIC) alleviated urinary tract infections (UTIs) in spinal cord injury (SCI) patients with neurogenic bladder (NB).</p><p><strong>Methods: </strong>A single-blind randomized controlled trial was conducted. Patients who developed UTIs while rehabilitating from SCI were enrolled continuously between January 2021 and March 2023 and randomly assigned to the control or the intervention group. Patients in the intervention group received LFBV twice daily (5-10 Hz, 5-10 min each time) for 10 days. The primary endpoint was urinary leucocytes, and various other UTI indexes were also tracked. The follow-up lasted four weeks.</p><p><strong>Results: </strong>The control group (n = 44) and the intervention group (n = 43) were indistinguishable in the basic patient characteristics. Compared to the control group, the intervention group has significantly higher urinary leucocytes on day 2 and significantly lower urinary leucocytes and urinary bacteria on day 10. Four weeks after LFBV, the intervention group had significantly lower urinary leucocytes and post-void residual volume, fewer signs and symptoms of urinary tract infection, as well as significantly higher urine volume. There was no significant change in urinary red blood cells or occult blood due to LFBV.</p><p><strong>Conclusion: </strong>Applying LFBV to SCI/NB patients with UTIs is recommended.</p>","PeriodicalId":14454,"journal":{"name":"International Urology and Nephrology","volume":" ","pages":"1689-1697"},"PeriodicalIF":1.8,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12049399/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142909672","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}